Testing a new drug with standard chemo for AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial adds an experimental drug called bleximenib to the usual chemotherapy for people newly diagnosed with AML who have certain genetic changes (NPM1 or KMT2A). The goal is to see if adding this drug helps the treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with AML (acute myeloid leukemia) and have an NPM1 or KMT2A gene change.
- You are able to receive strong chemotherapy and are in reasonably good health (able to do daily activities).
- Your kidneys and liver are working well enough based on blood tests.
- You have not received any prior chemotherapy or other treatment for AML.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BL-M11D1 combined with standard chemotherapy (cytarabine + daunorubicin) or a targeted therapy (venetoclax + azacitidine) for people with newly diagnosed acute myeloid leukemia (AML). It aims to see if this combination is safe and effective.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This study tests a radioactive form of the drug bleximenib in people with acute leukemia that has come back or not responded to treatment. It looks for specific genetic changes in the leukemia cells and may help researchers understand how the drug works in the body.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This trial tests a new combination of drugs (ABC-14) against the standard treatment for adults newly diagnosed with acute myeloid leukemia (AML) who haven't had intensive treatment yet. The goal is to see if the new combo works better and is safe.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.